Stock Ratings / Health Care / BBIO / forecast

LLY (72) JNJ (66) ABBV (71) UNH (70) ⌘ Pro Terminal →

BridgeBio Pharma Inc. (BBIO) 12-Month Stock Forecast & Price Target Cone

$70.73 -0.13% NASDAQ • Public Delayed / 60s Snapshot

BridgeBio Pharma Inc. (BBIO) receives a Roarable Rating of D+ (Sell) and flashes a Red SELL / AVOID warning (54/100 RQD Confidence). Our SEC filing scanner spotted paper earnings outpacing real operating cash flow (-14.4% (NI vs OCF)) while unpaid customer invoices grew—a classic sign to step aside until cash flow catches up.

ROARABLE D+ • SELL / AVOID Cap $13.83B

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D+

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-1.8% Base Target

WHALE OPTIONS TUG-OF-WAR:58% Call Buyers ($2.6M)

42% PutsMax Pain: $69.00

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your BBIO Position Size: $10,000

Shares at $70.73: 141.4 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $54.18

$7,660

$-2,340 (-23.4%)

12M Consensus BaseTarget $69.46

$9,820

$-180 (-1.8%)

12M Bull Case BreakoutTarget $98.09

$13,868

+$3,868 (+38.7%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (32 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 6

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$72	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$92	69%	B
JP MorganUS Large-Cap Research	SELL	$62	58%	C

🔴 SUNDAY NIGHT PREP • 7:00 PM ETHosted Live by Perry Belcher & Guest Forensic Quant Desk

Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring BBIO)

✓Live walkthrough of BBIO's RQD Radar, SEC cash-conversion gap & downside levels
✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
✓Includes instant 24/7 email alert whenever any of your stocks flip to Red

RQD INSIDER CLUB UPGRADE$49/YEAR

Want Plain-English AI Custom Indicators, Daily Pro Trader Video Clips & SMS Crash Alerts?

🤖 Try AI Indicator Builder ($49/yr VIP) →$100K Arena

BBIO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +5.40%📐 HORIZONTAL RANGE

2026-10-30O $72.85H $75.85L $71.90C $74.95VOL 5.77M

SUP: $62.46SMA50: $70.27SMA200: $72.74

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BBIO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BBIO Butterfly Map → + Track BBIO →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

25.5%/yr Implied 5Y Growth

vs. +126.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BBIO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BBIO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BBIO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

BBIO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is BBIO's 12-month stock price target?

BridgeBio Pharma Inc. (BBIO) carries a 12-month consensus base price target of $69.46 (-1.8% from $70.73), with a bull-case target of $98.09 and a bear-case floor of $54.18.

Is BBIO stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates BBIO D+ (Sell — SELL) with an RQD Confidence score of 54/100.

Direct Sub-Reports: BBIO RQD Cockpit BBIO 12M Forecast BBIO Earnings & Move BBIO Dividends & DRIP BBIO Insiders & 13F BBIO Whale Options BBIO Profit Sankey BBIO News & Why